<?xml version='1.0' encoding='utf-8'?>
<?xml-stylesheet type="text/xsl" href="/v2/static/oai2.xsl"?>
<OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
  <responseDate>2026-10-12T11:46:25Z</responseDate>
  <request identifier="oai:figshare.com:article/33811687" metadataPrefix="oai_dc" verb="GetRecord">https://api.figshare.com/v2/oai</request>
  <GetRecord>
    <record>
      <header>
        <identifier>oai:figshare.com:article/33811687</identifier>
        <datestamp>2026-09-15T17:39:43Z</datestamp>
        <setSpec>category_7</setSpec>
        <setSpec>category_21</setSpec>
        <setSpec>category_811</setSpec>
        <setSpec>category_106</setSpec>
        <setSpec>category_132</setSpec>
        <setSpec>category_134</setSpec>
        <setSpec>portal_5</setSpec>
        <setSpec>item_type_3</setSpec>
        <setSpec>month_year_09_2026</setSpec>
      </header>
      <metadata>
        <oai_dc:dc xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"  xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:dc="http://purl.org/dc/elements/1.1/" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
          <dc:title>&lt;p&gt;Quality assessment of selected studies.&lt;/p&gt;</dc:title>
          <dc:creator>Desalegn Dawit Assele (11302533)</dc:creator>
          <dc:creator>Yitayew Ewnetu Mohammed (20995640)</dc:creator>
          <dc:creator>Abera Gezume Ganta (18155892)</dc:creator>
          <dc:creator>Tadele Dana Darebo (3177465)</dc:creator>
          <dc:creator>Sileshi Demelash Sasie (23180443)</dc:creator>
          <dc:subject>Medicine</dc:subject>
          <dc:subject>Biotechnology</dc:subject>
          <dc:subject>Mathematical Sciences not elsewhere classified</dc:subject>
          <dc:subject>Science Policy</dc:subject>
          <dc:subject>Infectious Diseases</dc:subject>
          <dc:subject>Virology</dc:subject>
          <dc:subject>nos ), adapted</dc:subject>
          <dc:subject>improve virological success</dc:subject>
          <dc:subject>critical modifiable factor</dc:subject>
          <dc:subject>viral suppression outcomes</dc:subject>
          <dc:subject>viral load suppression</dc:subject>
          <dc:subject>84 – 8</dc:subject>
          <dc:subject>8 %– 83</dc:subject>
          <dc:subject>observed across studies</dc:subject>
          <dc:subject>antiretroviral therapy adherence</dc:subject>
          <dc:subject>5 %– 81</dc:subject>
          <dc:subject>2 &lt;/ sup</dc:subject>
          <dc:subject>analysis &lt;/ p</dc:subject>
          <dc:subject>good art adherence</dc:subject>
          <dc:subject>estimate pooled prevalence</dc:subject>
          <dc:subject>virologic suppression</dc:subject>
          <dc:subject>pooled prevalence</dc:subject>
          <dc:subject>good adherence</dc:subject>
          <dc:subject>8 %).</dc:subject>
          <dc:subject>observational studies</dc:subject>
          <dc:subject>39 studies</dc:subject>
          <dc:subject>final analysis</dc:subject>
          <dc:subject>analysis aimed</dc:subject>
          <dc:subject>art adherence</dc:subject>
          <dc:subject>systematic reviews</dc:subject>
          <dc:subject>systematic review</dc:subject>
          <dc:subject>strongly associated</dc:subject>
          <dc:subject>significantly associated</dc:subject>
          <dc:subject>review protocol</dc:subject>
          <dc:subject>relatively high</dc:subject>
          <dc:subject>prisma checklist</dc:subject>
          <dc:subject>plhiv ).</dc:subject>
          <dc:subject>odds ratio</dc:subject>
          <dc:subject>key determinant</dc:subject>
          <dc:subject>highlighting adherence</dc:subject>
          <dc:subject>google scholar</dc:subject>
          <dc:subject>global targets</dc:subject>
          <dc:subject>cochran ’</dc:subject>
          <dc:subject>assessed using</dc:subject>
          <dc:subject>19 ).</dc:subject>
          <dc:description>&lt;div&gt;
&lt;p&gt;Background&lt;/p&gt;&lt;p&gt;Antiretroviral therapy (ART) adherence is a key determinant of viral load suppression among people living with HIV (PLHIV). In Ethiopia, evidence on the magnitude of ART adherence and its effect on virological outcomes remains fragmented. This systematic review and meta-analysis aimed to estimate the pooled prevalence of ART adherence and viral load suppression, and to measure the association between adherence and viral suppression among PLHIV in Ethiopia.&lt;/p&gt;
&lt;p&gt;Methods&lt;/p&gt;&lt;p&gt;This systematic review and meta-analysis used the PRISMA checklist for systematic reviews and meta-analyses. The review protocol has been registered onPROSPERO:(CRD420251125899). PubMed, ScienceDirect, Scopus, Epistemonikos, and Google Scholar were searched. The quality of included articles has been evaluated with a Newcastle–Ottawa Scale (NOS), adapted for observational studies. A random-effects model using restricted maximum likelihood (REML) with Knapp–Hartung adjustment was used to estimate pooled prevalence and odds ratio. Heterogeneity was assessed using I&lt;sup&gt;2&lt;/sup&gt;, τ&lt;sup&gt;2&lt;/sup&gt;, and Cochran’s Q test.&lt;/p&gt;
&lt;p&gt;Results&lt;/p&gt;&lt;p&gt;A total of 39 studies were included in the final analysis. The pooled prevalence of good ART adherence was 79.4% (95% CI: 74.8%–83.4%), while the pooled viral load suppression rate was 77.5% (95% CI: 72.5%–81.8%). The pooled odds ratio showed that good ART adherence was strongly associated with viral load suppression (OR = 6.30, 95% CI: 4.84–8.19). Substantial heterogeneity was observed across studies for both adherence and viral suppression outcomes (I&lt;sup&gt;2&lt;/sup&gt; &gt; 90%).&lt;/p&gt;
&lt;p&gt;Conclusions&lt;/p&gt;&lt;p&gt;ART adherence and viral load suppression among PLHIV in Ethiopia are relatively high but remain below global targets. Good adherence was significantly associated with virologic suppression, highlighting adherence as a critical modifiable factor for achieving optimal treatment outcomes. Strengthening adherence support interventions is essential to improve virological success and advance progress toward HIV epidemic control.&lt;/p&gt;&lt;/div&gt;</dc:description>
          <dc:date>2026-09-15T17:39:37Z</dc:date>
          <dc:type>Dataset</dc:type>
          <dc:type>Dataset</dc:type>
          <dc:identifier>10.1371/journal.pone.0358352.s003</dc:identifier>
          <dc:relation>https://figshare.com/articles/dataset/_p_Quality_assessment_of_selected_studies_p_/33811687</dc:relation>
          <dc:rights>CC BY 4.0</dc:rights>
        </oai_dc:dc>
      </metadata>
    </record>
  </GetRecord>
</OAI-PMH>
